This is a single-arm, open label, Phase II study of Roflumilast in stable-state non-cystic
fibrosis bronchiectasis subjects.
Bronchiectasis refers to a suppurative lung condition characterized by pathological
dilatation of bronchi. The predominant aetiology of bronchiectasis in the Western population
is related to cystic fibrosis (CF), which is genetically determined. Bronchiectasis due to
other causes are generally grouped under the term "non-CF bronchiectasis", which accounts for
practically all cases that are seen commonly in Hong Kong and many other Chinese populations.
The main pathogenesis of non-CF bronchiectasis involves airway inflammation, abnormal mucus
clearance and bacterial colonization, resulting in progressive airway destruction and
distortion. The current treatment strategies mainly focus on targeting the key elements in
the pathogenesis of non-CF bronchiectasis.
In patients with bronchiectasis, there is also neutrophilic inflammation as in COPD. It is
hypothesized that roflumilast can improve airway inflammation, sputum volume and sputum
inflammatory markers in patients with bronchiectasis.
This study aims to investigate the effect of short-term (4-week) treatment with roflumilast
on neutrophilic airway inflammation in stable-state non-CF bronchiectasis.